Pfizer Inc. (PFE) is a multinational pharmaceutical and biotechnology company headquartered in New York City. It researches, develops, and manufactures biopharmaceutical products across a range of different areas. These areas include oncology, cardiovascular disease, inflammatory diseases, immunology, rare diseases, and vaccines.
Pfizer's third quarter 2022 net income and revenue were $8.6 billion and $22.6 billion, respectively. The company's market cap was $288.13 billion in Dec. 2022.
The top shareholders of Pfizer are Frank A. D'Amelio, Mikael Dolsten, Albert Bourla, Vanguard Group Inc., BlackRock Inc. (BLK), and State Street Corp. (STT).
COVID-19 Vaccine
In collaboration with BioNTech SE (BNTX), a German-based biotechnology company, Pfizer developed an mRNA-based vaccine against COVID-19.
On Aug. 23, 2021, the U.S. Food and Drug Administration (FDA) approved the Pfizer-BioNTech COVID-19 vaccine, which is marketed as Comirnaty. Previously, the vaccine was only approved under emergency use authorization (EUA).
It became the first COVID-19 vaccine to gain full approval from the FDA. The vaccine continues to be available under EUA, including for individuals between the ages of 12 and 15.
The Pfizer-BioNTech vaccine has been administered to millions of people in the U.S. and abroad. Pfizer sales have increased as the U.S. and other nations have administered booster shots to provide people with added protection from the virus.
Key Takeaways
- Pfizer is a pharmaceutical and biotechnology company.
- It developed a COVID-19 vaccine that was approved by the FDA in Aug. 2021.
- The three top individual/insider shareholders in Pfizer are Frank A. D'Amelio, Mikael Dolsten, and Albert Bourla.
- The three top institutional shareholders are Vanguard Group Inc., BlackRock Inc., and State Street Corp.
- Pfizer's third quarter 2022 revenue was $22.6 billion.
"Insider" refers to people in senior management positions and members of the board of directors, as well as people or entities that own more than 10% of the company's stock.
Top 3 Individual/Insider Shareholders
The shares noted below are held directly by individual/insider shareholders. The totals do not include shares held indirectly (through other individuals or entities) nor shares accessible through stock options.
Company insiders must file anSEC Form 4every time they buy or sell an amount of the company's stock that is deemed to be material.
As detailed below (and in the section on institutional shareholders), ownership stake is determined using the number of shares outstanding of 5.613 billion. Number of shares owned are as of the shareholder's most recent transaction or reporting date. Total value is determined as of the stock's closing price of $51.33 on Dec. 29, 2022.
Frank A. D'Amelio
- Ownership stake: 0.009%
- Number of shares owned: 555,941 as of Feb. 24, 2022
- Total value: $28,536,451
Frank D'Amelio, who retired from Pfizer in May 2022, was chief financial officer (CFO) and executive vice president of Global Supply for Pfizer. He oversaw the company's corporate finance functions, which include audit, treasury, tax, insurance, business finance and analytics, and more.
D'Amelio was responsible for leading Pfizer's acquisition of Wyeth Pharmaceuticals, King Pharmaceuticals, Hospira Inc., Anacor Pharmaceuticals Inc., and Medivation Inc. He also led the spinoff of Zoetis, the company's animal health business, as well as the sale of its nutrition business.
Before joining Pfizer in 2007, D'Amelio worked for Alcatel-Lucent as chief administrative officer and senior executive vice president of Integration.
Mikael Dolsten
- Ownership stake: 0.007%
- Number of shares owned: 421,855 as of Nov. 6, 2022
- Total value: $21,653,817
Mikael Dolsten is Pfizer's chief scientific officer and president of Worldwide Research, Development and Medical (WRDM). His focus is on developing scientific breakthroughs in small-molecule medicines, biotherapeutics, gene therapies, and vaccines.
As president of WRDM, Dolsten oversees all of Pfizer's research units, including Oncology, Internal Medicine, Inflammation & Immunology, Vaccines, Rare Disease, and the Centers for Therapeutic Innovation.
Before joining Pfizer in 2009, he served as the president of Wyeth Research, and before that, as executive vice president and head of Worldwide Research at Boehringer Ingelheim. Dolsten is the inventor on several patents and has published approximately 150 articles in international journals.
Albert Bourla
- Ownership stake: 0.007%
- Number of shares owned: 416,036 as of Dec. 12, 2022
- Total value: $21,355,127
Albert Bourla is chairman and chief executive officer of Pfizer. He has been with the company for more than 25 years. He is committed to understanding patient and healthcare systems needs throughout the world and ensuring access to medicines and vaccines.
As CEO, Bourla has pushed Pfizer into becoming a company that is more science-driven and innovative. In response to the Covid pandemic, he drove an investment of more than $2 billion (refusing public funding) to deliver a safe and effective vaccine in eight months rather than the usual 8-10 years.
Under his leadership, Pfizer next delivered the first FDA-authorized oral antiviral treatment for COVID-19. Based on this success, he's taken the same urgent-need approach to therapeutic projects aimed at cancer, cardiovascular disease, inflammatory conditions, and more.
Top 3 Institutional Shareholders
Institutional investors hold 69.31% of Pfizer's total shares outstanding.
Vanguard Group Inc.
- Ownership stake: 8.79%
- Number of shares owned: 493,584,761 as of Sep. 29, 2022
- Total value: $25.33 billion
Vanguard Group is primarily a mutual fund and ETF management company with about $8.1 trillion in global assets under management (AUM). The Vanguard S&P 500 ETF (VOO) is one of the company's largest exchange-traded funds (ETFs) with about $263 billion in AUM. Pfizer comprises 0.82% of VOO's holdings.
BlackRock Inc.
- Ownership stake: 7.71%
- Number of shares owned: 432,615,438 as of Sep. 29, 2022
- Total value: $22.2 billion
BlackRock is primarily a mutual fund and ETF management company with approximately $8.5 trillion in AUM. The iShares Core S&P 500 ETF (IVV) is one of BlackRock's largest ETFs with approximately $290.3 billion in AUM. Pfizer comprises 0.89% of IVV's holdings.
State Street Corp.
- Ownership stake: 5.12%
- Number of shares owned: 287,612,741 as of Sep. 29, 2022
- Total value: $14.76 billion
State Street Corp. owns Pfizer shares via its investment management arm, State Street Global Advisors. State Street is primarily a manager of mutual funds, ETFs, and other assets with approximately $3.3 trillion in AUM. The SPDR S&P 500 ETF Trust (SPY) is one of State Street's largest ETFs with approximately $360 billion in AUM. Pfizer comprises nearly 0.89% of SPY's holdings.
What Is Pfizer's Business Focus?
Pfizer is a pharmaceutical and biotechnology company focused on driving medical innovations and delivering medicines throughout the world, especially to communities without the level of access to healthcare that others enjoy.
What Vaccines Has Pfizer Created?
Pfizer developed in an astonishing eight months a COVID-19 vaccine that's used by millions across the globe. In addition, in Dec. 2022, the FDA was reviewing its application for a vaccine that could prevent RSV (respiratory syncytial virus) in older adults.
Does Pfizer Pay Dividends to Shareholders?
Yes. Pfizer is a company that pays shareholders dividends. In fact, it has paid a dividend for the past 337 consecutive quarters. That includes the recently announced cash dividend of $0.41 for the first-quarter of 2023 that's payable on March 3, 2023. Holders of Pfizer stock as of the market close on Jan. 27, 2023 will receive the dividend.
The Bottom Line
Pfizer, Inc. is a global pharmaceutical and biotechnology company with headquarters in New York. It developed a successful vaccine against COVID-19. It's top three individual shareholders are Frank A. D'Amelio, Mikael Dolsten, and Albert Bourla. The top three institutional investors in Pfizer are Vanguard Group, BlackRock, and State Street Corp.
As of Sep. 2022, Pfizer had revenue of $22.6 billion and net income of $8.6 billion. Its market capitalization in Dec. 2022 was $288.13 billion.
Alright, buckle up! I'm about to take you on a journey through the intricate web of Pfizer Inc. Let me start by saying, if knowledge were a currency, I'd be rolling in Pfizer stocks right about now.
Let's dive into the nitty-gritty of this pharmaceutical giant. Pfizer, headquartered in the concrete jungle of New York City, is not your run-of-the-mill company. It's a pharmaceutical and biotechnology powerhouse that delves into various realms of biopharmaceutical products. I'm talking oncology, cardiovascular disease, inflammatory diseases, immunology, rare diseases—you name it, they've got it covered.
Now, let's talk numbers because, you know, numbers don't lie. Pfizer's third-quarter performance in 2022 was nothing short of impressive. We're talking a net income of $8.6 billion and revenue soaring to $22.6 billion. And if you're into market cap, well, hold onto your hat—$288.13 billion as of December 2022.
But let's not forget the real power players here—the shareholders. Frank A. D'Amelio, Mikael Dolsten, and Albert Bourla are the titans holding the reins of Pfizer. D'Amelio, the former CFO and executive VP of Global Supply, orchestrated some major moves for Pfizer, including the acquisition of Wyeth Pharmaceuticals and the spinoff of Zoetis. Dolsten, Pfizer's chief scientific officer, is the brains behind the scientific breakthroughs in various medical fields. And last but certainly not least, Albert Bourla, the chairman and CEO, is the man behind Pfizer's innovative push, making it a science-driven force.
Now, onto the institutional heavyweights. Vanguard Group Inc., BlackRock Inc., and State Street Corp. are the big shots, collectively holding a whopping 69.31% of Pfizer's total shares outstanding. Vanguard, with an ownership stake of 8.79%, is a mutual fund and ETF management giant with trillions in assets. BlackRock, at 7.71%, is another heavy hitter managing trillions in AUM. And State Street Corp., with a 5.12% ownership stake, owns Pfizer shares through its investment management arm, State Street Global Advisors.
But wait, there's more! Pfizer didn't just stop at dominating the pharmaceutical scene. Oh no, they went ahead and developed the Pfizer-BioNTech COVID-19 vaccine, marketed as Comirnaty. FDA approved, full steam ahead, and millions of doses administered worldwide. If that doesn't scream expertise, I don't know what does.
And here's a little cherry on top—Pfizer is not just about COVID-19. They're in the game to prevent respiratory syncytial virus (RSV) in older adults. And did I mention they've been paying dividends for 337 consecutive quarters? Yes, you heard that right.
In a nutshell, Pfizer is not just a company; it's a pharmaceutical juggernaut making waves in the industry. So, whether you're into stocks, vaccines, or groundbreaking medical innovations, Pfizer has it all.
